Increased Myocardial Release of Prostacyclin in Dogs with Heart Failure

Walter H. Newman, Mary B. Frankis, Perry V. Halushka

Journal of Cardiovascular Pharmacology · 1983 · 28 citations · 0 references

Concepts

Abstract

We studied myocardial release of the endogenous vasodilator, prostacyclin, in dogs with cardiac hypertrophy and heart failure because of previous reports of reduced coronary blood flow reserve in various models of cardiac hypertrophy. Myocardial release of prostacyclin was estimated by measuring the concentration of its stable metabolite, 6-keto prostaglandin F1α (6-K F1α), found in a physiological buffer instilled into the pericardial space. In anesthetized dogs with chronic heart failure resulting from aortocaval fistula, the basal release of 6-KF1α was over twofold higher than normal. Dogs with heart failure released 1301 ± 226 pg 6-KF1α per square centimeter of ventricular surface area during the 4.5 min that the buffer was in the pericardial space compared to 553 ± 82 pg/cm2 for control dogs (p < 0.01). Simultaneously released thromboxane B2 (TxB2), the stable metabolite of the vasoconstrictor thromboxane A2, was measured and found not to be different in the two groups of dogs. In control dogs, isoproterenol administration was associated with a dose-dependent increase in myocardial release of 6-KF1α, while the release of TxB2 was constant. In contrast, 6-KF1α levels remained high and unaffected by isoproterenol administration in dogs with heart failure. These alterations in myocardial release of 6-KF1α were parallelled by changes in coronary vascular resistance. Resting coronary vascular resistance was significantly lower than normal in dogs with heart failure (0.8 ± 0.23 mm Hg·min/ml 1112 vs. 2.1 ± 0.1 mm Hg·min/ml control, p < 0.01). Coronary vascular resistance decreased in a dose-dependent manner in response to isoproterenol in control dogs but did not change in dogs with heart failure. These results are compatible with the idea that enhanced myocardial release of prostacyclin may play a role in the altered coronary vascular responses seen in heart failure.